Previous 10 | Next 10 |
home / stock / repcf / repcf news
Transaction represents RepliCel’s entrance i nto the U.S. market Investment terms minimize dilution and p uts RepliCel on-track for US FDA marketing approval s of the RepliCel Dermal I njector Product Line VANCOUVE...
VANCOUVER, British Columbia, Sept. 14, 2020 (GLOBE NEWSWIRE) -- RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel” or the “Company”), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to provide ...
Successful Annual General Meeting Confirms Director Slate for 2020 VANCOUVER , Dec. 23, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthoped...
Notable Milestones for the Company's Programs VANCOUVER , Nov. 26, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA: P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to p...
Clinical Data Published from RepliCel's Skin Rejuvenation Study Canada NewsWire VANCOUVER, Sept. 24, 2019 A paper entitled, "Autologous Cell Therapy for Aged Human Skin: A Randomized, Placebo-Controlled, Phase-I Study", has been published summarizing the data from...
YOFOTO ( China ) Health Now Commissioning its Manufacturing Facility in Preparation for Technology Transfer of Skin and Tendon Product Manufacturing and Applications for Clinical Trials VANCOUVER , Sept. 10, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FR...
Management strengthens its commitment to a successful upcoming market launch of RepliCel's dermal injector and consumables product line by addition of Damien King VANCOUVER , Aug. 29, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA: P6P2) ("RepliC...
Tendon Regeneration, Skin Rejuvenation and Dermal Injector Patents Granted in the United States , Europe , South Africa , Hong Kong, China , and Japan VANCOUVER , April 16, 2019 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" or the "C...
RepliCel's Licensee Building Momentum in China with Facility and Team Canada NewsWire VANCOUVER, March 26, 2019 YOFOTO ( China ) Health Announces Initiation of Facility Build-Out, New Hires, and Preparation to Submit Applications to China's Regulators VANCOUVER , Mar...
RepliCel Life Sciences ( OTCQB:REPCF ) announces the resumption of their First-in-Japan strategy. More news on: RepliCel Life Sciences Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
RepliCel Life Sciences Company Name:
REPCF Stock Symbol:
OTCMKTS Market:
RepliCel Life Sciences Website:
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developi...
Independent Testing Performed by Innovacell Demonstrates the DermaPrecise ™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability Consistency VANCOUVER, BC / ACCESSWIRE / August 2, 2022 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliC...
After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy products VANCOUVER, BC / ACCESSWIRE / July 28, 2022 / RepliCel Life Sciences ...